ストックスクリーナーアプリを入手
11.84
9.59%
-1.255
アフターアワーズ：
11.75
-0.085
-0.72%
前日終値:
$13.09
開ける：
$12.825
24時間の取引高:
1.14M
Relative Volume:
0.87
時価総額：
$760.09M
収益：
$161.10M
当期純損益:
$-308.60M
株価収益率:
-2.5343
EPS:
-4.67
ネットキャッシュフロー:
$-259.90M
1週間 パフォーマンス:
-8.68%
1か月 パフォーマンス:
-2.59%
6か月 パフォーマンス:
+74.30%
1年 パフォーマンス:
-34.07%
1日の値動き範囲:
$11.38
$12.92
1週間の範囲:
$11.38
$14.00
52週間の値動き範囲:
$5.90
$20.38
Arvinas Inc Stock (ARVN) Company Profile
Compare ARVN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
11.84 | 840.70M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-06 | アップグレード | Citigroup | Neutral → Buy |
| 2025-10-15 | ダウングレード | Goldman | Neutral → Sell |
| 2025-09-24 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-06-02 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | ダウングレード | Truist | Buy → Hold |
| 2025-05-02 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-02 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-13 | ダウングレード | Goldman | Buy → Neutral |
| 2025-03-12 | ダウングレード | Wedbush | Outperform → Neutral |
| 2025-03-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-11-18 | 開始されました | Stephens | Overweight |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2024-02-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-01 | 開始されました | Goldman | Buy |
| 2023-12-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-11-20 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-10-23 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-01-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | 開始されました | Barclays | Overweight |
| 2022-06-21 | 開始されました | Jefferies | Hold |
| 2022-05-09 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-04-06 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-02-11 | 再開されました | BMO Capital Markets | Outperform |
| 2022-02-10 | 開始されました | Wells Fargo | Overweight |
| 2022-01-19 | 開始されました | Goldman | Buy |
| 2021-12-07 | 開始されました | Cowen | Outperform |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-09 | 開始されました | BofA Securities | Buy |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-21 | 開始されました | Truist | Buy |
| 2021-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-12-14 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-06-01 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-12 | 開始されました | Oppenheimer | Perform |
| 2019-12-19 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-25 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | アップグレード | Goldman | Neutral → Buy |
| 2019-09-25 | 開始されました | Wedbush | Outperform |
| 2019-09-12 | 開始されました | BMO Capital Markets | Outperform |
| 2019-08-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-06-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-10-22 | 開始されました | Citigroup | Buy |
| 2018-10-22 | 開始されました | Goldman | Neutral |
| 2018-10-22 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Arvinas Inc (ARVN) 最新ニュース
Arvinas (NASDAQ:ARVN) Shares Down 10.9%Here's Why - MarketBeat
Arvinas announces appointment of Randy Teel, Ph.D., as president, chief executive officer, and director - marketscreener.com
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
New Haven-based biotech Arvinas names new CEO - Hartford Business Journal
Arvinas appoints Randy Teel as new CEO - Traders Union
Arvinas (ARVN) Appoints New CEO as Leadership Changes Unfold - GuruFocus
Arvinas Announces Leadership Transition and New CEO Appointment - TipRanks
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director - GlobeNewswire
(ARVN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - MSN
Arvinas, Inc. (ARVN) Stock Analysis: Unveiling Insights Into Its Biotech Potential - DirectorsTalk Interviews
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Market Moves: How does Radius Recycling Inc perform in inflationary periodsEarnings Miss & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Y Intercept Hong Kong Ltd Buys 137,794 Shares of Arvinas, Inc. $ARVN - MarketBeat
There Is A Reason Arvinas, Inc.'s (NASDAQ:ARVN) Price Is Undemanding - 富途牛牛
Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth - Sahm
Gains Recap: Can Arvinas Inc reach all time highs this yearWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Arvinas, Inc. (ARVN) Stock Analysis: Navigating The Biotech Frontier With Potential Upside - DirectorsTalk Interviews
Arvinas CEO John Houston to retire - MSN
New nanoparticle technology offers hope for hard-to-treat diseases - GlobeNewswire Inc.
Trading Systems Reacting to (ARVN) Volatility - Stock Traders Daily
Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN - MarketBeat
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 27.9% in December - MarketBeat
Metastatic Prostate Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart.com
Short Squeeze: Will Arvinas Inc stock gain from government policies2025 Institutional Moves & Precise Swing Trade Alerts - Bộ Nội Vụ
TAC to the future: Where induced proximity is pointing in 2026 - BioCentury
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug - MSN
Can Arvinas Inc. stock sustain institutional interestWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Why Arvinas Inc. stock remains on buy lists2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
How Arvinas Inc. (ARVN) Affects Rotational Strategy Timing - Stock Traders Daily
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Is Arvinas Inc. stock positioned well for digital economyPortfolio Return Report & Capital Efficiency Focused Ideas - ulpravda.ru
Movement Recap: Why Arvinas Inc. stock remains resilient2025 AllTime Highs & Expert Verified Movement Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - Улправда
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Sentiment Watch: Is Arvinas Inc. stock positioned for long term growthTrade Analysis Report & Risk Managed Investment Strategies - Улправда
Citigroup upgrades Arvinas (ARVN) - MSN
Citigroup Upgrades Arvinas (ARVN) - Nasdaq
Arvinas (NASDAQ:ARVN) Shares Gap UpTime to Buy? - MarketBeat
ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Down 2.6%Should You Sell? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Aug Patterns: Will Arvinas Inc stock remain a Wall Street favorite2025 Top Gainers & Safe Investment Capital Preservation Plans - moha.gov.vn
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotechnology Frontier with PROTAC Innovation - DirectorsTalk Interviews
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas Inc (ARVN) 財務データ
収益
当期純利益
現金流量
EPS
Arvinas Inc (ARVN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Morrison Briggs | Director |
Sep 22 '25 |
Buy |
7.57 |
30,000 |
227,010 |
76,021 |
| Saik Andrew | Chief Financial Officer |
Jun 24 '25 |
Sale |
7.61 |
5,700 |
43,377 |
164,401 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):